APR 2 9 2003

MAIL STOP AF 2 9 2003

2001 THE STOP AF 1600/2900

IN THE U.S. PATENT AND TRADEMARK OFFICE

TRANGAN application of: Amanda Johanne KILIAAN et al.

Conf.: 2164

Appl. No.:

09/703,798

Group: 1651

Filed:

November 2, 2000

Examiner: Ruth A Davis

Title:

PREPARATION FOR THE PREVENTION AND/OR

TREATMENT OF VASCULAR DISORDERS

REQUEST FOR CONTINUED EXAMINATION UNDER 37 C.F.R. § 1.114

Assistant Commissioner for Patents
Washington, DC 20231

April 24, 2003

Sir:

This is a "Request for Continued Examination" under 37 C.F.R. § 1.114, the provisions of which do not apply to:

- (1) A provisional application; (2) An application for a utility or plant patent filed under 35 U.S.C. 111(a) before June 8, 1995; (3) An international application filed under 35 U.S.C. §363 before June 8, 1995; (4) An application for a design patent; or (5) A patent under reexamination.
- ☐ This Request for Continued Examination is being filed prior to the earliest of:
 - (1) Payment of the issue fee, unless a petition under \$1.313 is granted; (2) Abandonment of the application; or (3) The filing of a notice of appeal to the U.S. Court of Appeals for the Federal Circuit under 35 U.S.C. § 141, or the commencement of civil action under 35 U.S.C. §§ 145 or 146, unless the appeal or civil action is terminated.
- The enclosed document is being transmitted via the Certificate of Mailing provisions of 37 C.F.R. § 1.8.
- The enclosed document is being transmitted via facsimile.
- Submission Required under 37 C.F.R. § 1.114:

Enter as part of the present submission:

An After Final Amendment previously filed on , under 37 C.F.R. § 1.116 but unentered, in the present application.

04/25/2003 HDEMESS1 00000023 09703798

01 FC:1801

750.00 OP

	ts in the sly filed o	e Appeal n .	Brief or	Reply	Brief
		le 1.111, ted as set			Claim
	TOTAL NUMBER OF CLAIMS PREVIOUSLY FILED	TOTAL NUMBER OF CLAIMS BEING FILED HEREWITH	NUMBER EXTRA	RATE	FEE
Total Claims				x\$18 =	\$0.0
Independent Claims				x\$84 =	\$0.0
			TOTAL CLA	IM FEE(S)	\$0.0
1449 f		sclosure St /are atta ration.			l PTO- the
□ Other:					
<u>Fees</u>					
The required 37 C.F.R. § herewith:					
	.00 - small .00 - large	_			
The applican () m 1.136(a). Th	onth(s) pu	rsuant to	37 C.F.R.	§§ 1.1	7 and
in the require	nsions of to prior appled for the ton of time.	time have b ication. Th full period	een previnus, a fe of the a	ously obt e of \$0. bove-requ	tained 00 is wested
An exte request applica obtain	nsion of ed and pa: tion. Thus, an addition	() id for on , a fee of al (month(s) in \$0.00 i) month	was previ n the ir s requir (s) exten	lously istant ed to sion.
Enclosed is applicable extension fe	filing fee				
Please charg	e Deposit triplicate	Account No.	25-0120 s sheet is	in the a	amount d.

 \boxtimes

 \boxtimes

Application No. 09/703,798 Docket No. 2001-1165

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

YOUNG & THOMPSON

Philip A. BuBois, Reg. No. 50,696

745 South 23rd Street Arlington, VA 22202 Telephone (703) 521-2297

PD/fb

Attachments

Revised 0/0/0000



APR 2 9 2003

Atty. Docket No. 2001-1165

TECH CENTER 1600 2900

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Amanda Johanne KILIAAN et al.

Confirmation No. 2164

Serial No. 09/703,798

GROUP 1651

Filed November 2, 2000

Examiner Ruth A Davis

PREPARATION FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISORDERS

<u>AMENDMENT</u>

Commissioner for Patents

Washington, D.C. 20231

Sir:

Responsive to the Official Action of August 22, 2002, please amend the above-identified application as follows:

IN THE CLAIMS:

Amend claim 19 as follows:

19. (amended) A preparation for the prevention/treatment of dementia syndromes, cognitive degeneration or hearing loss, comprising the following fractions:

fraction a) consisting of long chain polyunsaturated fatty acids containing at least one member selected from the group consisting of eicosapentaenoic acid (EPA), docasahexaenoic acid (DHA), dihomogammalinolenic acid (DHGLA), arachidonic acid (AA), linoleic acid and α -linoleic acid, wherein the ratio of the total amount of EPA + DHA + DHGLA + AA to the total amount of

